Menin molecular interactions: Insights into normal functions and tumorigenesis

Hormone and Metabolic Research

Volumn 37, Issue 6, 2005, Pages 369-374

  Agarwal, S K ^a,d   Kennedy, P A ^a   Scacheri, P C ^b   Novotny, E A ^b   Hickman, A B ^a   Cerrato, A ^a   Rice, T S ^a   Moore, J B ^a   Rao, S ^a   Ji, Y ^b   Mateo, C ^a   Libutti, S K ^c   Oliver, B ^a   Chandrasekharappa, S C ^b   Burns, A L ^a   Collins, F S ^b   Spiegel, A M ^d   Marx, S J ^a  

^a NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

^b NATIONAL HUMAN GENOME RESEARCH INSTITUTE   (United States)

^c NATIONAL CANCER INSTITUTE   (United States)

^d NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

Hox genes; Jund; Men1; MLL; Multiple endocrine neoplasia; Oncogene; Partners; Transcription; Tumor suppressor

Indexed keywords

BONE MORPHOGENETIC PROTEIN 2; CYTOPLASM PROTEIN; CYTOSKELETON PROTEIN; DEOXYRIBONUCLEOPROTEIN; EXTRACHROMOSOMAL DNA; HOX PROTEIN; METHIONINE; NUCLEAR PROTEIN; PROTEIN C FOS; PROTEIN C JUN; PROTEIN P18; PROTEIN P27; TRANSCRIPTION FACTOR; TUMOR NECROSIS FACTOR ALPHA;

AUTOSOMAL DOMINANT INHERITANCE; CARCINOGENESIS; DNA REPAIR; GENE MUTATION; GENE OVEREXPRESSION; GROWTH INHIBITION; HETEROZYGOSITY; HOX GENE; MOLECULAR INTERACTION; MULTIPLE ENDOCRINE NEOPLASIA; NONHUMAN; NUCLEAR LOCALIZATION SIGNAL; ONCOGENE C FOS; PRIORITY JOURNAL; REVIEW; SEQUENCE ANALYSIS; TUMOR SUPPRESSOR GENE;

ANIMALS; CELL NUCLEUS; CYTOSKELETAL PROTEINS; DNA; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MULTIPLE ENDOCRINE NEOPLASIA TYPE 1; PROTEIN BINDING; PROTO-ONCOGENE PROTEINS; TRANSCRIPTION FACTORS; TRANSCRIPTION, GENETIC;

EID: 22444445436     PISSN: 00185043     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2005-870139     Document Type: Review

References (57)

1. Marx SJ. In: The Genetic Basis of Human Cancer. Vogelstein B and Kinzler KW (eds). Multiple endocrine neoplasia type 1. New York: McGraw Hill, 2002: 475-450
2. Dean PG, van Heerden JA, Farley DR et al. Are patients with multiple endocrine neoplasia type 1 prone to premature death? World J Surg 2000;24:1437-1441
3. Eng C. RET proto-oncogene in the development of human cancer. J Clin Oncol 1999;17: 380-393
4. Yaguchi H, Ohkura N, Takahashi M, Nagamura Y, Kitabayashi I. Tsukada T. Menin missense mutants associated with multiple endocrine neoplasia type 1 are rapidly degraded via the ubiquitin-proteasome pathway. Mol Cell Biol 2004; 24: 6569-6580
5. Crabtree JS, Scacheri PC, Ward JM et al. A mouse model of multiple endocrine neoplasia, type 1, develops multiple endocrine tumors. Proc Natl Acad Sci USA 2001; 98: 1118-1123
6. Suphapeetiporn K, Busygina V, Xu T, Bale AE. Drosophila homolog of human multiple endocrine neoplasia type I gene (MEN1) interacts with Jun and Fos in vivo. Am J Hum Genet, 2001; 69 (Suppl): 156 (Abstract)
7. Cerrato A, Santa Anna AS, Marx S et al. The Drosophila homolog of the human tumor suppressor gene MEN1 functions in the thoracic closure pathway. Annual Dros Res Conf 2002; 43: 546C (Abstract)
8. Lin SY, Elledge SJ. Multiple tumor suppressor pathways negatively regulate telomerase. Cell 2003; 113: 881-889
9. Kim YS, Burns AL, Goldsmith PK et al. Stable overexpression of MEN1 suppresses tumorigenicity of RAS. Oncogene 1999; 18: 5936-5942
10. Bertolino P, Radovanovic I, Casse H, Aguzzi A, Wang ZQ, Zhang CX. Genetic ablation of the tumor suppressor menin causes lethality at mid-gestation with defects in multiple organs. Mech Dev 2003; 120: 549-560
11. Bertolino P, Tong WM, Galendo D, Wang ZQ, Zhang CX. Heterozygous Men1 mutant mice develop a range of endocrine tumors mimicking multiple endocrine neoplasia type 1. Mol Endocrinol 2003; 17: 1880-1892
12. Libutti SK, Crabtree JS, Lorang D et al. Parathyroid gland-specific deletion of the mouse Men1 gene results in parathyroid neoplasia and hypercalcemic hyperparathyroidism. Cancer Res 2003; 63: 8022-8028
13. Crabtree JS, Scacheri PC, Ward JM et al. Of mice and MEN1: Insulinomas in a conditional mouse knockout. Mol Cell Biol 2003; 23: 6075-6085
14. Bertolino P, Tong WM, Herrera PL, Casse H, Zhang CX, Wang ZQ. Pancreatic beta-cell-specific ablation of the multiple endocrine neoplasia type 1 (MEN1) gene causes full penetrance of insulinoma development in mice. Cancer Res 2003; 63: 4836-4841
15. Biondi CA, Gartside MG, Waring P et al. Conditional inactivation of the MEN1 gene leads to pancreatic and pituitary tumorigenesis but does not affect normal development of these tissues. Mol Cell Biol 2004; 24: 3125-131
16. Scacheri PC, CrabtreeJS, Kennedy AL et al. Tissue specificity of a tumor suppressor: homozygous loss of menin is well tolerated in hepatocytes. Ninth international workshop on multiple endocrine neoplasia (MEN 2004) June 20-23, 2004 Hyatt Regency Hotel, Bethesda, MD. Hot Topics Abstracts: Page 21
17. Agarwal SK, Guru SC, Heppner C et al. Menin interacts with the AP1 transcription factor JunD and represses JunD-activated transcription. Cell 1999; 96: 143-152
18. Gobi AE, Berg M, Lopez-Egido JR, Oberg K, Skogseid B, Westin G. Menin represses JunD-activated transcription by a histone deacetylase-dependent mechanism. Biochim Biophys Acta 1999; 1447: 51-56
19. Ikeo Y, Yumita W, Sakurai A, Hashizume K. JunD-menin interaction regulates c-Jun-mediated AP-1 transactivation. Endocr J 2004; 51: 333-342
20. Knapp JI, Heppner C, Hickman AB et al. Identification and characterization of JunD missense mutants that lack menin binding. Oncogene 2000; 19: 4706-4712
21. Kim H, Lee JE, Cho EJ, Liu JO, Youn HD. Menin, a tumor suppressor, represses JunD-mediated transcriptional activity by association with an mSin3A-histone deacetylase complex. Cancer Res 2003; 63: 6135-6139
22. Mechta-Grigoriou F, Gerald D, Yaniv M. The mammalian Jun proteins: redundancy and specificity. Oncogene 2001; 20: 2378-2389
23. Jochum W, Passegue E, Wagner EF. AP-1 in mouse development and tumorigenesis. Oncogene 2001; 20: 2401-2412
24. Heppner C, Bilimoria KY, Agarwal SK et al. The tumor suppressor protein menin interacts with NF-kappaB proteins and inhibits NF-kappaB-mediated transactivation. Oncogene 2001; 20: 4917-4925
25. Perkins ND. The Rel/NF-kappa B family: friend and foe. Trends Biochem Sci. 2000; 25: 434-440
26. Lemmens IH, Forsberg L, Pannett AA et al. Menin interacts directly with the homeobox-containing protein Pem. Biochem Biophys Res Commun 2001; 286: 426-431
27. Kaji H, Canaff L, Lebrun JJ, Goltzman D, Hendy GN. Inactivation of menin, a SmadS-interacting protein, blocks transforming growth factor type beta signaling. Proc Natl Acad Sci USA 2001; 98: 3837-3842
28. Sowa H, Kaji H, Canaff L et al. Inactivation of menin, the product of the multiple endocrine neoplasia type 1 gene, inhibits the commitment of multipotential mesenchymal stem cells into the osteoblast lineage. J Biol Chem 2003; 278: 21058-21069
29. Sowa H, Kaji H, Hendy GN et al. Menin is required for BMP-2- and TGF-beta-regulated osteoblastic differentiation through interaction with Smads and Runx2. J Biol Chem 2004; 279: 40267-40275
30. Hughes CM, Rozenblatt-Rosen O, Milne TA et al. Menin associates with a trithorax family histone methyltransferase complex and with the hoxcS locus. Mol Cell 2004; 13: 587-597
31. Yokoyama A, Wang Z, Wysocka J et al. Leukemia proto-oncoprotein MLL forms a SET1-like histone methyltransferase complex with menin to regulate Hox gene expression. Mol Cell Biol 2004; 24: 5639-5649
32. Miller T, Krogan NJ, Dover J et al. COMPASS: a complex of proteins associated with a trithorax-related SET domain protein. Proc Natl Acad Sci USA, 2001; 98: 12902-12907
33. Rozenblatt-Rosen O, Hughes CM, Nannepaga SJ, Shanmugam KS, Copeland TD, Guszczynski T, Resau JH, Meyerson M. The parafibromin tumor suppressor protein is part of a human Paf1 complex. Mol Cell Biol 2005; 25: 612-620
34. Krogan NJ, Dover J, Wood A et al. The Paf1 complex is required for histone H3 methylation by COMPASS and Dot1p: linking transcriptional elongation to histone methylation. Mol Cell 2003; 11: 721-729
35. Mueller CL, Jaehning JA. Ctr9, Rtf1, and Leol are components of the Paf1/RNA polymerase 11 complex. Mol Cell Biol 2002; 22: 1971-1980
36. Carpten JD, Robbins CM, Villablanca A et al. HRPT2, encoding parafibromin, is mutated in hyperparathyroidism-jaw tumor syndrome. Nat Genet 2002; 32: 676-680
37. Sukhodolets KE, Hickman AB, Agarwal SK et al. The 32-kilodalton subunit of replication protein A interacts with menin, the product of the MEN1 tumor suppressor gene. Mol Cell Biol 2003; 23: 493-509
38. Jin S, Mao H, Schnepp RW et al. Menin associates with FANCD2, a protein involved in repair of DNA damage. Cancer Res 2003; 63: 4204-4210
39. La P, Silva AC, Hou Z et al. Direct binding of DNA by tumor suppressor menin. J Biol Chem 2004; 279: 49045-49054
40. Obungu VH, Lee Burns A, Agarwal SK, Chandrasekharapa SC, Adelstein RS, Marx SJ. Menin, a tumor suppressor, associates with nonmuscle myosin U-A heavy chain. Oncogene 2003; 22: 6347-6358
41. Lopez-Egido J, Cunningham J, Berg M, Oberg K, Bongcam-Rudloff E, Gobi A. Menin's interaction with glial fibrillary acidic protein and vimentin suggests a role for the intermediate filament network in regulating menin activity. Exp Cell Res 2002; 278: 175-183
42. Ohkura N, Kishi M, Tsukada T, Yamaguchi K. Menin, a gene product responsible for multiple endocrine neoplasia type 1, interacts with the putative tumor metastasis suppressor nm23. Biochem Biophys Res Commun 2001; 282: 1206-1210
43. Yaguchi H, Ohkura N, Tsukada T, Yamaguchi K. Menin, the multiple endocrine neoplasia type 1 gene product, exhibits GTP-hydrolyzing activity in the presence of the tumor metastasis suppressor nm23. J Biol Chem 2002; 277: 38197-381204
44. Stalberg P, Grimfjard P, Santesson M et al. Transfection of the multiple endocrine neoplasia type 1 gene to a human endocrine pancreatic tumor cell line inhibits cell growth and affects expression of JunD, delta-like protein 1/preadipocyte factor-1, proliferating cell nuclear antigen, and QM/Jif-1. J Clin Endocrinol Metab 2004; 89: 2326-2337
45. Agarwal SK, Novotny EA, Crabtree JS et al. Transcription factor JunD, deprived of menin, switches from growth suppressor to growth promoter. Proc Natl Acad Sci USA 2003; 100: 10770-10775
46. La P, Schnepp RW, Petersen CD, Silva AC, Hua X. Tumor suppressor menin regulates expression of insulin-like growth factor binding protein 2. Endocrinology 2004; 145: 3443-3450
47. Schnepp RW, Mao H, Sykes SM et al. Menin induces apoptosis in murine embryonic fibroblasts. J Biol Chem 2004; 279: 10685-10691
48. Milne TA, Briggs SD, Brock HW et al. MLL targets SET domain methyltransferase activity to Hox gene promoters. Mol Cell 2002; 10: 1107-1117
49. Sayo Y, Murao K, Imachi H et al. The multiple endocrine neoplasia type 1 gene product, menin, inhibits insulin production in rat insulinoma cells. Endocrinology 2002; 143: 2437-2440
50. Namihira H, Sato M, Murao K et al. The multiple endocrine neoplasia type 1 gene product, menin, inhibits the human prolactin promoter activity. J Mol Endocrinol 2002; 29: 297-304
51. Gallo A, Cuozzo C, Esposito I et al. Menin uncouples Elk-1, JunD and c-Jun phosphorylation from MAP kinase activation. Oncogene 2002; 21: 6434-6445
52. Varro A, Hemers E, Archer D et al. Identification of plasminogen activator inhibitor-2 as a gastrin-regulated gene: Role of Rho GTPase and menin. Gastroenterology 2002; 123: 271-280
53. Yumita W, Ikeo Y, Yamauchi K, Sakurai A, Hashizume K. Suppression of insulin-induced AP-1 transactivation by menin accompanies inhibition of c-Fos induction. Int J Cancer 2003; 103: 738-744
54. Lacerte A, Lee EH, Reynaud R et al. Activin inhibits pituitary prolactin expression and cell growth through Smads, Pit-1 and menin. Mol Endocrinol 2004; 18: 1558-1569
55. Hendy GN. Menin and TGF-beta superfamily member signaling via the Smad pathway in pituitary, parathyroid, and osteoblast. Horm Metab Res 2005; 37: 375-379
56. Busygina V, Suphapeetiporn K, Marek LR, Stowers RS, Xu T, Bale AE. Hypermutability in a Drosophila model for multiple endocrine neoplasia type 1. Hum Mol Genet 2004; 13: 2399-2408
57. Franklin DS, Godfrey VL, O'Brien DA, Deng C, Xiong Y. Functional collaboration between different cyclin-dependent kinase inhibitors suppresses tumor growth with distinct tissue specificity. Mol Cell Biol 2000; 20: 6147-6158